No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 26 of the 40 quarters in the window, leaving 14 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 152.4x · 10Y median 73.5x · 79th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T21:47:47.593Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T21:47:47.593Z. Latest historical point 2025-11-12.
The latest delayed quote for PAVmed Inc. (PAVM) stock was $2.68 as of Oct 6, 2026, 4:00 PM EDT, up 0.56% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -79.5% · 3-year avg -72.3%/yr · 5-year avg -76.5%/yr
PAVmed Inc. operates as a U.S.-based medical technology firm.
Medical - Devices · New York City, NY
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2022-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.63
Revenue Est.
$25000.00
Last Quarter Results
EPS
$-0.27
vs Estimate
$-0.63
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PAVM | $17.07M | $2.67 | +0.56% | -79.49% | -76.55% | -54.03% | N/A |
| 2MRKR | $16.84M | $1.01 | -4.72% | +11.06% | -42.13% | -33.25% | vs PAVM |
| 3LPCN | $17.31M | $2.10 | +1.45% | -38.07% | -34.76% | -29.99% | vs PAVM |
| 4TCRX | $16.82M | $0.28 | -6.74% | -85.87% | -48.85% | N/A | vs PAVM |
| 5COSM | $17.39M | $0.32 | -7.58% | -67.82% | -68.41% | -45.52% | vs PAVM |
| 6PTN | $16.74M | $9.41 | -0.74% | +20.66% | -55.41% | -35.08% | vs PAVM |
N/A
$33000.00
vs Estimate
$48000.00
Consensus Rating
Based on 2 analysts
Average Price Target
$36.50
+1264.5% upside
Low
$16.00
Current
$2.67
High
$57.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.75 | $-0.59 | $-0.43 | 1 |
| Quarter ending Dec 2026 | $-0.71 | $-0.56 | $-0.41 | 1 |
| Quarter ending Mar 2027 | $-0.64 | $-0.50 | $-0.36 | 1 |
| Quarter ending Jun 2027 | $-0.64 | $-0.50 | $-0.36 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-4.26 | $-3.62 | $-2.98 | 1 |
| FY 2027 | $-2.33 | $-1.98 | $-1.63 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $19696.00 | $25000.00 | $30303.00 | 1 |
| Quarter ending Dec 2026 | $102424.00 | $130000.00 | $157575.00 | 1 |
| Quarter ending Mar 2027 | $68939.00 | $87500.00 | $106060.00 | 1 |
| Quarter ending Jun 2027 | $88636.00 | $112500.00 | $136363.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $200902.00 | $232500.00 | $264097.00 | 1 |
| FY 2027 | $518458.00 | $600000.00 | $681541.00 | 1 |
